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Background/methods
The CAPP2 Study evaluated 600mg enteric coated
aspirin and/or 30gms of Novelose (resistant starch) in a
double blind factorial RCT in 1071 carriers of Lynch
syndrome over a treatment period of 1 to 4 years, mean
29 months.
Results
The trial, reported in December 2008 [1], showed that
there was no difference between the treatment and pla-
cebo groups for new colorectal neoplasia. Follow-up data
for 667 participants for up to 120 months (mean 51m) is
now available. Analysis reveals a striking reduction in
subsequent cancers; overall, 102 participants have devel-
oped 110 Lynch syndrome cancers. Despite equal num-
bers being randomised to aspirin or placebo, cancer
sufferers in the aspirin group are outnumbered 2 to 1.
Lifetable analysis for time to first Lynch syndrome cancer
reveals a hazard ration of 0.62(0.41, 0.96)p=0.03. There
is a clear effect of duration of treatment: <24months on
treatment OR 0.90 (0.45, 1.81) p=0.78, treated >24
months OR 0.50 (0.28, 0.86) p=0.01.
Conclusions
All carriers of Lynch syndrome should consider aspirin
chemoprevention. A dose finding study, CAPP3, is
under development. It will compare different doses of
aspirin over a 5 to 10 year period.
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